Amide proton transfer MRI differentiates between progressive multifocal leukoencephalopathy and malignant brain tumors: a pilot study

Abstract

Abstract Background Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nerve system caused by the John Cunningham virus. On MRI, PML may sometimes appear similar to primary central nervous system lymphoma (PCNSL) and glioblastoma multiforme (GBM). The purpose of this pilot study was to evaluate the potential of amide proton transfer (APT) imaging for differentiating PML from PCNSL and GBM. Methods Patients with PML (n = 3; two men; mean age 52.0 ± 7.0 years), PCNSL (n = 7; four women; mean age 74.4 ± 5.8 years), or GBM (n = 11; 6 men; mean age 65.0 ± 15.2 years) who underwent APT-CEST MRI between January 2021 and July 2022 were retrospectively evaluated. Magnetization transfer ratio (MTR) values were measured on APT imaging using a region of interest within the lesion. Receiver operating characteristics curve analysis was used to determine diagnostic cutoffs for MTR. Results The mean MTR values were 0.005 ± 0.006 in the PML group, 0.025 ± 0.005 in the PCNLS group, and 0.025 ± 0.009 in the GBM group. There were significant differences in MTR between PML and PCNSL (P = 0.050), and between PML and GBM (P = 0.039). For differentiating PML from PCNSL, an MTR threshold of 0.0165 gave diagnostic sensitivity, specificity, positive predictive value, and negative predictive value of 100% (all). For differentiating PML from GBM, an MTR threshold of 0.015 gave diagnostic sensitivity, specificity, positive predictive value, and negative predictive value of 90.9%, 100%, 100%, and 97.6%, respectively. Conclusion MTR values obtained from APT imaging allowed patients with PML to be clearly discriminated from patients with PCNSL or GBM.